logo
Twitter
Discord
Email
logo
Benitec Biopharma Inc.

Benitec Biopharma Inc.

NASDAQ•BNTC
CEO: Dr. Jerel A. Banks M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-06-24
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Contact Information
3940 Trust Way, Hayward, CA, 94545, United States
510-780-0819
benitec.com
Market Cap
$306.57M
P/E (TTM)
-10.4
38.2
Dividend Yield
--
52W High
$17.15
52W Low
$9.70
52W Range
27%
Rank48Top 64.4%
3.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.22-54.17%
4-Quarter Trend

FCF

-$3.35M-26.93%
4-Quarter Trend

2026 Q1 Earnings Highlights

Key Highlights

Strong Cash Position Maintained Cash reserves total $94.6M end of period, significantly higher than $67.9M held at September 30, 2024.
BB-301 Clinical Success Noted BB-301 Cohort 1 achieved 100% statistical response rate; FDA granted Fast Track designation for OPMD treatment.
Reduced Operating Cash Burn Cash used in operations reduced to $3.35M this quarter, compared to $4.59M used in the prior comparable period.
Lead Asset Development Progress BB-301 is the lead agent for OPMD; strategy focuses on advancing clinical trials through key inflection points.

Risk Factors

Net Loss Significantly Widened Net loss increased to $9.0M for the quarter, compared to $5.1M loss reported in the prior year period.
G&A Expense Driven by Stock General administrative expenses rose sharply to $6.43M, primarily due to $5.18M in share-based compensation expense.
Internal Control Material Weakness Material weakness identified in internal controls over share-based compensation calculation review process; remediation is underway.
Dependence on Future Financing Expect continued operating losses; ability to continue as going concern depends on obtaining adequate financing resources.

Outlook

Post-Period Financing Closed Closed November 2025 offerings raising approximately $100M gross proceeds before deducting underwriting discounts and fees.
BB-301 Trial Follow-up Continues Continue BB-301 Phase 1b/2a trial follow-up; interim safety and efficacy results expected to be available every 180 days.
ATM Facility Remains Available Maintain access to $75M Sales Agreement for future capital needs; no sales utilized during the current reporting quarter.
Future Funding Requirements Uncertain Future capital needs depend heavily on clinical trial costs, regulatory timing, and successful intellectual property defense.

Peer Comparison

Revenue (TTM)

Amarin Corporation plcAMRN
$225.62M
-6.7%
Cellectis S.A.CLLS
$75.27M
+158.9%
DiaMedica Therapeutics Inc.DMAC
$13.80M
-55.2%

Gross Margin (Latest Quarter)

Korro Bio, Inc.KRRO
100.0%
+0.0pp
Lineage Cell Therapeutics, Inc.LCTX
99.9%
+0.9pp
Cellectis S.A.CLLS
93.3%
+10.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RAPT$580.47M-9.0-61.8%1.6%
DSGN$528.62M-7.8-30.6%0.8%
DBVT$497.09M-3.3-295.2%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 13, 2026
|
EPS:-$0.23
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q1 2026

    Period End: Sep 30, 2025|Filed: Nov 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.22-54.2%
    N/A

  • Form 10-K - FY 2025

    Period End: Jun 30, 2025|Filed: Sep 22, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.05+60.8%
    N/A

  • Form 10-Q - Q3 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.24+4.3%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Dec 31, 2024|Filed: Feb 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.33-75.0%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Sep 30, 2024|Filed: Nov 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.48-65.2%
    N/A

  • Form 10-K - FY 2024

    Period End: Jun 30, 2024|Filed: Sep 26, 2024|
    Revenue: $216.00K+188.0%
    |
    EPS: $-2.68+81.0%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $6.00K-88.9%
    |
    EPS: $-0.23-91.4%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Dec 31, 2023|Filed: Feb 13, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-1.32-18.0%
    N/A